UBS raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $523 from $458 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals Reports Strong Growth Amid Challenges
- Madrigal Pharmaceuticals: Strategic Growth and Market Potential Driven by Rezdiffra’s Success and Key Acquisitions
- Cautious Outlook on Madrigal Pharmaceuticals: Sell Rating Amid Competitive Pressures and Valuation Concerns
- Madrigal Pharmaceuticals price target raised to $428 from $420 at Canaccord
- Madrigal Pharmaceuticals Reports Strong Q2 2025 Results